NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
Findings from this research are vital to NIAID's efforts to advance vaccines, drugs, and diagnostic tools to better diagnose, prevent, and treat infectious diseases.
Cerba Research will provide clinical laboratory screening and safety testing for NIAID-supported clinical trials within the infectious disease area.
Cerba Research is a healthcare company with end-to-end drug development and diagnostic solutions to optimize R and D drug productivity and commercialization.
Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Cerba Research works with government agencies, non-government organisations as well as pharma and biotech organisations to change the shape of clinical development.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
NIAID is composed of 7 research divisions: the Division of AIDS; the Division of Allergy, Immunology, and Transplantation; the Division of Clinical Research; the Division of Extramural Activities; the Division of Intramural Research; the Division of Microbiology and Infectious Diseases; and the Dale and Betty Bumpers Vaccine Research Center. NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville, and Frederick, Maryland, and in Hamilton, Montana.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results